Transcatheter Aortic Valve Implantation in Mixed Aortic Valve Disease: A Multicenter Study

• Published in: The American journal of cardiology Vol. 203; pp. 394 - 402
• Main Authors: Guddeti, Raviteja R., Gill, Gauravpal S., Parekh, Jai D., Jhand, Aravdeep S., Walters, Ryan W., Panaich, Sidakpal S., Goldsweig, Andrew M., Alla, Venkata Mahesh
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.09.2023; Elsevier Limited
• Subjects: Aorta; Aortic stenosis; Aortic valve; Balloon treatment; Clinical outcomes; Complications; Diabetes; Ejection fraction; Heart valves; Implantation; mixed aortic valve disease; Mortality; Statistical analysis; Stroke; Thorax; Tomography; transcatheter aortic valve implantation; Transplants & implants; Ultrasonic imaging; transcatheter aortic valve implantation; aortic stenosis; mixed aortic valve disease
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2023.07.064

Mixed aortic valve disease (MAVD), defined by the concurrent presence of aortic stenosis (AS) and insufficiency is frequently seen in patients who have undergone transcatheter aortic valve implantation (TAVI). However, studies comparing the outcomes of TAVI in MAVD versus isolated AS have demonstrated conflicting results. Therefore, we aim to assess the outcomes of TAVI in patients with MAVD in comparison with those with isolated severe AS. Patients who underwent native valve TAVI for severe AS at 3 tertiary care academic centers between January 2012 and December 2020 were included and categorized into 3 groups based on concomitant aortic insufficiency (AI) as follows: group 1, no AI; group 2, mild AI; and group 3, moderate to severe AI. Outcomes of interest included all-cause mortality and all-cause readmission rates at 30 days and 1 year. Other outcomes include bleeding, stroke, vascular complications, and the incidence of paravalvular leak at 30 days after the procedure. Of the 1,588 patients who underwent TAVI during the study period, 775 patients (49%) had isolated AS, 606 (38%) had mild AI, and 207 (13%) had moderate to severe AI. Society of Thoracic Surgeons risk scores were significantly different among the 3 groups (5% in group 1, 5.5% in group 2, and 6% in group 3, p = 0.003). Balloon-expandable valves were used in about 2/3 of the population. No statistically significant differences in 30-day or 1-year all-cause mortality and all-cause readmission rates were noted among the 3 groups. Post-TAVI paravalvular leak at follow-up was significantly lower in group 1 (2.3%) and group 2 (2%) compared with group 3 (5.6%) (p = 0.01). In summary, TAVI in MAVD is associated with comparable outcomes at 1 year compared with patients with isolated severe AS.